Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

Summary

The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-threatening condition that is usually found when patients are children.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications